Company Active LTD

Company profile

The Native Antigen Company Limited

The Native Antigen Company

Welcome to The Native Antigen Company. we are world-leading infectious disease reagents from the experts. Whether you need cutting edge reagents for your research or bulk products for manufacturing we can support all of your needs.

CRN
07386339
Founded
2010
Age
15

Overview

Legal name
THE NATIVE ANTIGEN COMPANY LIMITED
Region
South East England
Registered address
THE PRIESTLEY CENTRE 10 PRIESTLEY ROAD
SURREY RESEARCH PARK
GUILDFORD
ENGLAND
GU2 7XY
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

15 levels 1 ultimate controller
1
Company Active LTD
The Native Antigen Company Limited
CRN 07386339
2
Direct controller Active LTD
LGC (Holdings) Limited
CRN 03141667
3
Intermediate controller Active LTD
4
Intermediate controller Active LTD
5
Intermediate controller Active LTD
6
Intermediate controller Active LTD
7
Intermediate controller Active LTD
Teddington 2 Limited
CRN 07110936
8
Intermediate controller Active LTD
9
Intermediate controller Active LTD
Teddington 3 Limited
CRN 09903564
10
Intermediate controller Active LTD
Elwy 3 Limited
CRN 09905519
11
Intermediate controller Active LTD
Elwy 2 Limited
CRN 09905091
12
Intermediate controller Active LTD
Loire UK Bidco Limited
CRN 12315743
13
Intermediate controller Active LTD
14
Intermediate controller Active LTD
15
Intermediate controller Active LTD
16
Ultimate controller Active LTD

Company events

Reference milestones and recent Companies House filing stream events.

11 events
31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

07 Oct
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

23 Sep
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

25 Nov
2024

Accounts With Accounts Type Total Exemption Full

Accounts PDF pending

AA | Transaction MzQ0NDc4MzYzMWFkaXF6a2N4 | Paper/PDF filed

Published 27 Nov 2024 10:42

25 Nov
2024

Legacy

Accounts PDF pending

PARENT_ACC | Transaction MzQ0NDc4MzIyNGFkaXF6a2N4 | Paper/PDF filed

Published 25 Nov 2024 02:27

25 Nov
2024

Legacy

Other

AGREEMENT2 | Transaction MzQ0NDc4MzAwN2FkaXF6a2N4 | Paper/PDF filed

Published 25 Nov 2024 02:25

25 Nov
2024

Legacy

Other

GUARANTEE2 | Transaction MzQ0NDc4MjkwOGFkaXF6a2N4 | Paper/PDF filed

Published 25 Nov 2024 02:23

30 Sep
2024

Termination Secretary Company With Name Termination Date

Officers

TM02 | Transaction MzQzNzczMjcwMmFkaXF6a2N4

Published 30 Sep 2024 12:16

23 Sep
2024

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzQzNjgzNDY3NmFkaXF6a2N4

Published 23 Sep 2024 11:25

23 Sep
2010

Incorporated

Inception

Company registered at Companies House

Public funding

6 awards
First funded
2012
Funded years
2012, 2013, 2014, 2016, 2017
Age at first award
1 years

Projects

2017 Collaborative R&D Lead participant

Development of a point-of-care, non-crossreacting Zika diagnostic test

1 Jan 2017 to 30 Sep 2018

Awarded
£319,324
Total cost £456,177

At the start of 2016, Zika virus hit the headlines with an outbreak in Brazil far larger than any seen before, causing a huge rise in the number of children born with smaller than average heads and other abnormalities. As this virus is relatively recent, there are very few diagnostic methods of detecting the disease it causes, and most of the currently av...

2016 GRD Proof of Concept Lead participant

Development of a novel, rapid and safe neutralising antibody diagnostic kit by The Native Antigen Company

1 Mar 2016 to 28 Feb 2017

Awarded
£100,000
Total cost £186,714

Diagnostic tests are a vital component of disease diagnosis and vaccine research. For any test, the important parameters are sensitivity (i.e. the ability of the test to correctly identify a positive sample) and specificity (i.e. its ability to discriminate correctly between different diseases). Most diagnostic tests are simple plate-based assays or pregn...

2014 GRD Proof of Concept Lead participant

A novel approach using VLP's to enhance the immunogenicity of peptides for generation of therapeutic Monoclonal antibodies.

1 Aug 2014 to 31 Jul 2015

Awarded
£98,908
Total cost £164,901

The global market for therapeutic monoclonal antibodies (mAbs) has become the fastest growing segment of the pharmaceutical industry. The antigen is the lynchpin of therapeutic mAb development, so understanding, controlling and engineering antigens to increase immunogenicity is of vital interest to the pharmaceutical and diagnostic industry. Despite the s...

2013 Feasibility Studies Lead participant

A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.

1 Feb 2013 to 31 Jan 2014

Awarded
£109,828
Total cost £146,438

The Native Antigen Company (NAC) proposes to examine the technical feasibility of developing a novel mammalian cell expression system which would overcome the current barriers to producing suitable antigens from enveloped viruses for use as vaccine candidates. Our innovative approach would centre on the provision of pure Virus-Like Particles (VLPs) contai...

2013 GRD Proof of Concept Lead participant

The purification and production of toxins from emergent Clostridium difficile hypervirulent strains for use in Vaccine Research

1 Jan 2013 to 31 Mar 2014

Awarded
£70,000
Total cost £119,998

Clostridium difficile infection (CDI) is a major cause of morbidity and mortality in economically developed countries. CDI is primarily linked with hospital admission and prior antimicrobial treatment. Although significant advances have been made to reduce incidence, a number of hypervirulent and highly transmissible strains have recently emerged. Resulta...

2012 GRD Proof of Concept Lead participant

The Native Antigen Company - Native antigens for rapid point of care diagnostics

1 Mar 2012 to 28 Feb 2013

Awarded
£33,039
Total cost £55,066

Early detection of infectious disease offers the greatest opportunity to contain potential outbreaks, save lives and decrease the economic burden of healthcare. Rapid diagnostic test kits are one of the most effective ways to achieve this, allowing health care workers or members of the public to identify disease in the community. These tests, usually in t...

Product types

Collaborative R&D Feasibility Studies GRD Proof of Concept